Who owns ARRIVENT BIOPHARMA INC COM?
- CUSIP Number: 04272n102
Tip: Access positions for across all investors
Analyze quarterly positions in Arrivent Biopharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Arrivent Biopharma stock
Who bought or sold ARRIVENT BIOPHARMA INC COM this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| OrbiMed Advisors | 3.0M | $54M | 100% | Mar 2024 |
|
| FMR | 2.0M | $35M | 100% | Mar 2024 |
|
| Octagon Capital Advisors | 1.9M | $35M | 100% | Mar 2024 |
|
| Sofinnova Ventures | 1.7M | $30M | 100% | Mar 2024 |
|
| Suvretta Capital Management | 1.6M | $28M | 100% | Mar 2024 |
|
| General Catalyst Group Management | 1.5M | $27M | 100% | Mar 2024 |
|
| Sc China Holding | 663k | $11M | 100% | Mar 2024 |
|
| BlackRock | 655k | $12M | 100% | Mar 2024 |
|
| Vanguard Group | 649k | $12M | 100% | Mar 2024 |
|
| Cormorant Asset Management | 515k | $9.2M | 100% | Mar 2024 |
|
| Perceptive Advisors | 415k | $7.4M | 100% | Mar 2024 |
|
| Citadel Advisors | 287k | $5.1M | 100% | Mar 2024 |
|
| Geode Capital Management | 225k | $4.0M | 100% | Mar 2024 |
|
| Millennium Management | 212k | $3.8M | 100% | Mar 2024 |
|
| Farallon Capital Management | 152k | $2.7M | 100% | Mar 2024 |
|
| Woodline Partners | 100k | $1.8M | 100% | Mar 2024 |
|
| AlphaCentric Advisors | 83k | $1.5M | 100% | Mar 2024 |
|
| Northern Trust | 78k | $1.4M | 100% | Mar 2024 |
|
| Charles Schwab Investment Management | 78k | $1.4M | 100% | Mar 2024 |
|
| Jane Street | 37k | $660k | 100% | Mar 2024 |
|
| Point72 Asset Management | 29k | $516k | 100% | Mar 2024 |
|
| UBS O'Connor | 26k | $468k | 100% | Mar 2024 |
|
| Walleye Trading Advisors | 25k | $447k | 100% | Mar 2024 |
|
| Blackstone Group | 25k | $447k | 100% | Mar 2024 |
|
| Bank of New York Mellon | 23k | $406k | 100% | Mar 2024 |
|
| Point72 | 22k | $391k | 100% | Mar 2024 |
|
| Morgan Stanley | 21k | $378k | 100% | Mar 2024 |
|
| Barclays | 14k | $254k | 100% | Mar 2024 |
|
| Nuveen Asset Management | 13k | $231k | 100% | Mar 2024 |
|
| Jpmorgan Chase & Co | 13k | $224k | 100% | Mar 2024 |
|
| UBS Group | 9.9k | $177k | 100% | Mar 2024 |
|
| Rhumbline Advisers | 9.8k | $174k | 100% | Mar 2024 |
|
| Bnp Paribas Arbitrage, Snc | 4.7k | $83k | 100% | Mar 2024 |
|
| Cubist Systematic Strategies | 4.4k | $78k | 100% | Mar 2024 |
|
| Wells Fargo & Company | 3.2k | $58k | 100% | Mar 2024 |
|
| Bank of America Corporation | 2.3k | $40k | 100% | Mar 2024 |
|
| Citigroup | 1.7k | $31k | 100% | Mar 2024 |
|
| OTR - Nominee Name for The State Teachers Retirement Board of Ohio | 1.7k | $30k | 100% | Mar 2024 |
|
| California State Teachers Retirement System | 989.00 | $18k | 100% | Mar 2024 |
|
| Summit Investment Advisors | 981.00 | $18k | 100% | Mar 2024 |
|
| Legal & General Group | 896.00 | $16k | 100% | Mar 2024 |
|
| Tower Research Capital | 604.00 | $11k | 100% | Mar 2024 |
|
| Amalgamated Bank | 540.00 | $10k | 100% | Mar 2024 |
|
| Royal Bank of Canada | 369.00 | $7.7k | 100% | Mar 2024 |
|